Rezultati - L.C. Vermeer
- Showing 1 - 2 results of 2
-
1
Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands od Christine M. Cramer‐van der Welle, Marjon V. Verschueren, M. Tonn, Bas Peters, Franz M.N.H. Schramel, Olaf H. Klungel, Harry J.M. Groen, E.M.W. van de Garde, Elisabeth A. Kastelijn, L.C. Vermeer, B. E. E. M. van den Borne, J.W.G. van Putten, J. H. Schouwink, Annet Smit
Izdano 2021Artigo -
2
The toxicity profile of pemetrexed in non-small cell lung cancer patients with moderate renal impairment - a retrospective cohort study od Mart P. Kicken, Rob ter Heine, Intissar Azarfane, Nikki de Rouw, Fenna de Vries, Bas Peters, Nienke A. G. Lankheet, Frank Eektimmerman, Tim Beerden, Eric J. F. Franssen, L. L. Krens, Cor H. van der Leest, Arthur A. J. Smit, Albert J. Polman, L.C. Vermeer, John W.G. van Putten, Ben E.E.M. van den Borne, Michel M. van den Heuvel, Maarten J. Deenen
Izdano 2025Artigo
Iskalna orodja:
Sorodne teme
Cancer
Internal medicine
Lung cancer
Medicine
Oncology
Atezolizumab
Biology
Chemotherapy
Cisplatin
Clinical trial
Cohort
Computer science
Confidence interval
Data science
Hazard ratio
Immunotherapy
Nivolumab
Paleontology
Pembrolizumab
Pemetrexed
Real world data
Retrospective cohort study
Stage (stratigraphy)
Toxicity